Tatva Chintan Pharma Chem Ltd IPO

Last Updated: 03 January 2022 8:09 AM by 5Paisa

Offer Details:
The offer consists of Fresh Issue of Equity Shares aggregating upto ₹225 Crore and Offer for sale of Equity Shares aggregating upto ₹ 275Cr.
 

Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:

1. Funding capital expenditure requirements for expansion of our Dahej Manufacturing Facility;
2. Funding capital expenditure requirements for upgradation at our R&D facility in Vadodara; and
3. General corporate purposes.

Tatva Chintan Pharma Chem Shareholding 

_Source:RHP

Tatva Chintan Pharma Chem Limited is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (“SDAs”), phase transfer catalysts (“PTCs”), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (“PASC”). 

The company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. (Source: F&S Report) In addition, Tatva Chintan Pharma Chem is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. (Source: F&S Report). Considering the wide application of our products, the company serve customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavour and fragrances industries. Apart from the company’s customers in India, it also export our products to over 25 countries, including the USA, China, Germany, Japan, South Africa, and the UK. During the Fiscals ended March 31, 2019, 2020, and 2021, exports of products amounted to ₹ 1,435.19 million, ₹ 2,020.20 million and ₹ 2,119.92 million, which accounted for 69.57%, 76.74%, and 70.58%, of our revenue from operations, respectively.

_{Source: RHP}